J Neurol Surg A Cent Eur Neurosurg
DOI: 10.1055/a-2111-5698
Hank Shipman
1
Department of Internal Medicine, University of Utah, Salt Lake City, Utah, United States
,
Molly Monsour
2
University of South Florida Morsani College of Medicine, Tampa, Florida, United States
,
Madeline M. Foley
1
Department of Internal Medicine, University of Utah, Salt Lake City, Utah, United States
,
Serge Marbacher
3
Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland
,
4
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, United States
5
Department of Neurosurgery and Brain Repair, University of South Florida, Tampa, Florida, United States
,
4
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, United States
› Author Affiliations
Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
› Further Information
Also available at
![SFX Search]()
Buy Article Permissions and Reprints
Abstract
Traumatic spinal cord injuries (SCI) result in devastating impairment to an individual's functional ability. The pathophysiology of SCI is related to primary injury but further propagated by secondary reactions to injury, such as inflammation and oxidation. The inflammatory and oxidative cascades ultimately cause demyelination and Wallerian degeneration. Currently, no treatments are available to treat primary or secondary injury in SCI, but some studies have shown promising results by lessening secondary mechanisms of injury. Interleukins (ILs) have been described as key players in the inflammation cascade after neuronal injury; however, their role and possible inhibition in the context of acute traumatic SCIs have not been widely studied. Here, we review the relationship between SCI and IL-6 concentrations in the CSF and serum of individuals after traumatic SCIs. Furthermore, we explore the dual IL-6 signaling pathways and their relevance for future IL-6 targeted therapies in SCI.
Keywords
spinal cord injury -
interleukin-6 -
neuroinflammation -
trauma -
pathophysiology
Publication History
Received: 24 August 2022
Accepted: 14 June 2023
Accepted Manuscript online:
16 June 2023
Article published online:
03 July 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Lim SW,
Shiue YL,
Ho CH.
et al.
Anxiety and depression in patients with traumatic spinal cord injury: a nationwide population-based cohort study. PLoS One 2017; 12 (01) e0169623
2
National Spinal Cord Injury Statistical Center.
Facts and Figures at a Glance. Birmingham, AL: University of Alabama at Birmingham; 2021
3
Lo J,
Chan L,
Flynn S.
A systematic review of the incidence, prevalence, costs, and activity and work limitations of amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury in the United States: a 2019 update. Arch Phys Med Rehabil 2021; 102 (01) 115-131
4
Chio JCT,
Xu KJ,
Popovich P,
David S,
Fehlings MG.
Neuroimmunological therapies for treating spinal cord injury: evidence and future perspectives. Exp Neurol 2021; 341: 113704
5
Fehlings MG,
Wilson JR,
Harrop JS.
et al.
Efficacy and safety of methylprednisolone sodium succinate in acute spinal cord injury: a systematic review. Global Spine J 2017; 7 (03) 116S-137S
6
Liu Z,
Yang Y,
He L.
et al.
High-dose methylprednisolone for acute traumatic spinal cord injury: a meta-analysis. Neurology 2019; 93 (09) e841-e850
7
Wilson JR,
Fehlings MG.
Riluzole for acute traumatic spinal cord injury: a promising neuroprotective treatment strategy. World Neurosurg 2014; 81 (5–6): 825-829
8
Chow DS,
Teng Y,
Toups EG.
et al.
Pharmacology of riluzole in acute spinal cord injury. J Neurosurg Spine 2012; 17 (01) 129-140
9
Ahuja CS,
Nori S,
Tetreault L.
et al.
Traumatic spinal cord injury—repair and regeneration. Neurosurgery 2017; 80 (3S): S9-S22
10
Yoshida Y,
Tanaka T.
Interleukin 6 and rheumatoid arthritis. BioMed Res Int 2014; 2014: 698313
11
Monsour M,
Croci DM,
Grüter BE,
Taussky P,
Marbacher S,
Agazzi S.
Cerebral aneurysm and interleukin-6: a key player in aneurysm generation and rupture or just one of the multiple factors?. Transl Stroke Res 2023; 14: 631-639
12
Rothaug M,
Becker-Pauly C,
Rose-John S.
The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta 2016; 1863 (6 Pt A): 1218-1227
13
Schuett H,
Oestreich R,
Waetzig GH.
et al.
Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012; 32 (02) 281-290
14
Hirota H,
Kiyama H,
Kishimoto T,
Taga T.
Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J Exp Med 1996; 183 (06) 2627-2634
15
Chucair-Elliott AJ,
Conrady C,
Zheng M,
Kroll CM,
Lane TE,
Carr DJ.
Microglia-induced IL-6 protects against neuronal loss following HSV-1 infection of neural progenitor cells. Glia 2014; 62 (09) 1418-1434
16
Yang P,
Wen H,
Ou S,
Cui J,
Fan D.
IL-6 promotes regeneration and functional recovery after cortical spinal tract injury by reactivating intrinsic growth program of neurons and enhancing synapse formation. Exp Neurol 2012; 236 (01) 19-27
17
Yunna C,
Mengru H,
Lei W,
Weidong C.
Macrophage M1/M2 polarization. Eur J Pharmacol 2020; 877: 173090
18
Guerrero AR,
Uchida K,
Nakajima H.
et al.
Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice. J Neuroinflammation 2012; 9: 40
19
Ma SF,
Chen YJ,
Zhang JX.
et al.
Adoptive transfer of M2 macrophages promotes locomotor recovery in adult rats after spinal cord injury. Brain Behav Immun 2015; 45: 157-170
20
Cao Z,
Gao Y,
Bryson JB.
et al.
The cytokine interleukin-6 is sufficient but not necessary to mimic the peripheral conditioning lesion effect on axonal growth. J Neurosci 2006; 26 (20) 5565-5573
21
Monsour M,
Croci DM,
Agazzi S.
The role of IL-6 in TBI and PTSD, a potential therapeutic target?. Clin Neurol Neurosurg 2022; 218: 107280
22
Fernández M,
Baldassarro VA,
Capirossi R.
et al.
Possible strategies to optimize a biomarker discovery approach to correlate with neurological outcome in patients with spinal cord injury: a pilot study. J Neurotrauma 2020; 37 (03) 431-440
23
Yang L,
Blumbergs PC,
Jones NR,
Manavis J,
Sarvestani GT,
Ghabriel MN.
Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury. Spine 2004; 29 (09) 966-971
24
Kwon BK,
Stammers AM,
Belanger LM.
et al.
Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J Neurotrauma 2010; 27 (04) 669-682
25
de Mello Rieder M,
Oses JP,
Kutchak FM.
et al.
Serum biomarkers and clinical outcomes in traumatic spinal cord injury: prospective cohort study. World Neurosurg 2019; 122: e1028-e1036
26
Roberts TT,
Leonard GR,
Cepela DJ.
Classifications In Brief: American Spinal Injury Association (ASIA) Impairment Scale. Clin Orthop Relat Res 2017; 475 (05) 1499-1504
27
Kwon BK,
Streijger F,
Fallah N.
et al.
Cerebrospinal fluid biomarkers to stratify injury severity and predict outcome in human traumatic spinal cord injury. J Neurotrauma 2017; 34 (03) 567-580
28
Dalkilic T,
Fallah N,
Noonan VK.
et al.
Predicting injury severity and neurological recovery after acute cervical spinal cord injury: a comparison of cerebrospinal fluid and magnetic resonance imaging biomarkers. J Neurotrauma 2018; 35 (03) 435-445
29
Capirossi R,
Piunti B,
Fernández M.
et al.
Early CSF biomarkers and late functional outcomes in spinal cord injury. a pilot study. Int J Mol Sci 2020; 21 (23) 9037
30
Uciechowski P,
Dempke WCM.
Interleukin-6: a masterplayer in the cytokine network. Oncology 2020; 98 (03) 131-137
31
Hu JG,
Shi LL,
Chen YJ.
et al.
Differential effects of myelin basic protein-activated Th1 and Th2 cells on the local immune microenvironment of injured spinal cord. Exp Neurol 2016; 277: 190-201
32
Mukaino M,
Nakamura M,
Yamada O.
et al.
Anti-IL-6-receptor antibody promotes repair of spinal cord injury by inducing microglia-dominant inflammation. Exp Neurol 2010; 224 (02) 403-414
33
Guptarak J,
Wanchoo S,
Durham-Lee J.
et al.
Inhibition of IL-6 signaling: A novel therapeutic approach to treating spinal cord injury pain. Pain 2013; 154 (07) 1115-1128
34
Leibinger M,
Zeitler C,
Gobrecht P,
Andreadaki A,
Gisselmann G,
Fischer D.
Transneuronal delivery of hyper-interleukin-6 enables functional recovery after severe spinal cord injury in mice. Nat Commun 2021; 12 (01) 391
35
Briukhovetska D,
Dörr J,
Endres S,
Libby P,
Dinarello CA,
Kobold S.
Interleukins in cancer: from biology to therapy. Nat Rev Cancer 2021; 21 (08) 481-499
36
Hellenbrand DJ,
Quinn CM,
Piper ZJ,
Morehouse CN,
Fixel JA,
Hanna AS.
Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration. J Neuroinflammation 2021; 18 (01) 284
37
Biggioggero M,
Crotti C,
Becciolini A,
Favalli EG.
Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther 2018; 13: 57-70
38
Bijlsma JWJ,
Welsing PMJ,
Woodworth TG.
et al.
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 2016; 388 (10042): 343-355
39
Bongartz T.
Tocilizumab for rheumatoid and juvenile idiopathic arthritis. Lancet 2008; 371 (9617) 961-963
40
Hill JA,
Menon MP,
Dhanireddy S.
et al.
Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. J Med Virol 2021; 93 (04) 2270-2280
41
Wise J.
Covid-19: arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows. BMJ 2021; 372 (433) n433
42
Zhao M,
Lu J,
Tang Y,
Dai Y,
Zhou J,
Wu Y.
Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies. Eur J Clin Pharmacol 2021; 77 (03) 311-319
43
Croci DM,
Wanderer S,
Strange F.
et al.
Tocilizumab reduces vasospasms, neuronal cell death, and microclot formation in a rabbit model of subarachnoid hemorrhage. Transl Stroke Res 2021; 12 (05) 894-904
Comments (0)